Stock NYMXF NYMOX PHARMACEUTICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Nymox Pharmaceutical Corporation

Equities

NYMXF

BSP733981026

Market Closed - OTC Markets
Other stock markets
 15:37:09 09/05/2024 BST 		5-day change 1st Jan Change
0.2505 USD -10.62% Intraday chart for Nymox Pharmaceutical Corporation -10.54% -57.54%
2023 Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
CI
Fed Outlook Weighs on Exchange-Traded Funds, Equity Futures Premarket Thursday
MT
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Nymox Pharmaceutical Gets Nasdaq Extension to Comply With Listing Requirements; Shares Rise
MT
Nymox Pharmaceutical Corporation Announces New Marketing Submission for Nymozarfex for BPH
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
NYMOX Receives RTF letter from FDA
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Nymox Pharma Seeks FDA Marketing Nod for Fexapotide Triflutate Drug Candidate; Shares Rise
MT
Nymox Pharmaceutical Corporation Announces Submission of New Drug Application to the FDA for Fexapotide Triflutate
CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Nymox Pharmaceutical : Expects to Provide Guidance on Fexapotide Regulatory Filing This Quarter; Shares Drop
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NYMXF Stock
  4. News Nymox Pharmaceutical Corporation
  5. Highlights